Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
New COPD Drugs: 2019 in Review
FDA 2019 approvals for COPD treatment included a cryotherapy spray and other novel & breakthrough therapies. Updates at-a-glance, here.
For primary care and other clinicians who treat COPD, 2019 was a year of innovation.FDA approved the first once-daily nebulized bronchodilator; a Breakthrough Device that delivers cryotherapy; and, the first generic of Advair Diskus. In other developments, aspirin was found to reduce COPD mortality and macrolides to reduce frequency of acute exacerbations.Scroll through the slides below for short summaries of these and other news important to optimal management of COPD.
Related Content
